On-site monitoring and therapy control of infections using circulating free DNA
EPI-CARE focuses on the development and research of a rapid analysis system for the quantification of circulating cell-free DNA (cfDNA) for on-site surveillance of epidemic infectious diseases. In the current care of SARS-CoV-2 infected patients, no reliable and effective methods exist for this purpose. Similarly, progression prediction that allows early therapy and optimized management of limited capacity is not currently available. The project addresses this problem with a rapid analysis system that relies on the quantitative molecular biological analysis of cfDNA.
The aim of the EPI-CARE rapid analysis system is to perform a precise risk stratification based on measurements of the cfDNA concentration in order to achieve a de-escalation of the individual disease course.
BYTEC took over the project coordination and successfully submitted the outline together with the cooperation partners R-Biopharm AG, Fraunhofer Institute for Microtechnology and Microsystems (IMM), Johannes Gutenberg University Mainz and University Medicine of the Johannes Gutenberg University Mainz.